An FDA advisory panel approved a lower dose of the Pfizer candidate for kids ages 5 to 11. The vaccine approval will now go to the CDC.
An independent advisory panel for the Food and Drug Administration approved a lower dose of the Pfizer candidate for kids ages 5 to 11 on Tuesday, in a major step toward providing coronavirus vaccines for 28 million children in the United States. The vote from the Vaccines and Related Biological Products Advisory Committee came with 17 members in support and one abstention; agency officials could now give final approval as early as this week.
